Garg Nidhi, Pekmezaris Renee, Stevens Gerin, Becerra Adan Z, Kozikowski Andrzej, Patel Vidhi, Haddad Ghania, Levy Phillip, Kumar Pridha, Becker Lance
Northwell Health, Southside Hospital, Department of Emergency Medicine, Bayshore, New York.
Northwell Health, Department of Internal Medicine, Manhasset, New York.
West J Emerg Med. 2021 Apr 8;22(3):672-677. doi: 10.5811/westjem.2021.1.48978.
The purpose of this study was to validate and assess the performance of the Emergency Heart Failure Mortality Risk Grade (EHMRG) to predict seven-day mortality in US patients presenting to the emergency department (ED) with acute congestive heart failure (CHF) exacerbation.
We performed a retrospective chart review on patients presenting to the ED with acute CHF exacerbation between January 2014-January 2016 across eight EDs in New York. We identified patients using codes from the International Classification of Diseases, 9th and 10 Revisions, or who were diagnosed with CHF in the ED. Inclusion criteria were patients ≥ 18 years of age who presented to the ED for acute CHF. Exclusion criteria included the following: end-stage renal disease related heart failure; < 18 years of age; pregnancy; palliative care; renal failure; and "do not resuscitate" directive. The primary outcome was seven-day mortality. We used mixed-effects logistic regression models to estimate C-statistics and continuous net reclassification index for events and nonevents.
We identified 3,320 ED visits associated with suspected CHF among 2,495 unique patients. Of the 3,320 ED visits, 94.7% patients were admitted to the hospital and 3.4% were discharged. The median age was 78.6 (interquartile range 68.01 - 86.76). There was an overall seven-day mortality of 2%, an inpatient mortality rate of 2.4%, and no mortality among the discharge group. Adding EHMRG to the risk prediction model improved the C-statistic (from 0.748 to 0.772) and led to a higher degree of reclassification for both events and nonevents.
The EHMRG can be used as a valuable and effective screening tool in the US while considering disposition decision for patients with acute CHF exacerbation. Emergency medical services transport and metolazone use is much higher in the US population as compared to the Canadian population. We observed minimal to no short-term mortality among discharged CHF patients from the ED.
本研究旨在验证和评估急诊心力衰竭死亡率风险分级(EHMRG)预测美国急诊科(ED)急性充血性心力衰竭(CHF)加重患者七天死亡率的性能。
我们对2014年1月至2016年1月期间纽约市八个急诊科中因急性CHF加重而就诊的患者进行了回顾性病历审查。我们使用国际疾病分类第9版和第10版的编码来识别患者,或者在急诊科被诊断为CHF的患者。纳入标准为年龄≥18岁且因急性CHF到急诊科就诊的患者。排除标准包括以下情况:终末期肾病相关心力衰竭;年龄<18岁;怀孕;姑息治疗;肾衰竭;以及“不要复苏”指令。主要结局为七天死亡率。我们使用混合效应逻辑回归模型来估计事件和非事件的C统计量以及连续净重新分类指数。
我们在2495名独特患者中确定了3320次与疑似CHF相关的急诊科就诊。在这3320次急诊科就诊中,94.7%的患者入院,3.4%的患者出院。中位年龄为78.6岁(四分位间距68.01 - 86.76)。总体七天死亡率为2%,住院死亡率为2.4%,出院组无死亡病例。将EHMRG添加到风险预测模型中可提高C统计量(从0.748提高到0.772),并导致事件和非事件的重新分类程度更高。
在美国,对于急性CHF加重患者进行处置决策时,EHMRG可作为一种有价值且有效的筛查工具。与加拿大人群相比,美国人群中紧急医疗服务转运和使用美托拉宗的情况要高得多。我们观察到急诊科出院的CHF患者短期死亡率极低或无短期死亡率。